Every Form 4 that Sensei Biotherapeutics, Inc. (SNSE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNSE filings page.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported open-market purchases of a total of 13,634 shares of common stock over three days. On June 29 and 30, 2026, and July 1, 2026, the trust bought multiple blocks of shares at weighted average prices disclosed in the filing, including 4,400 shares at $23.40 and 4,255 shares at $24.98. Following the latest transaction, the trust holds 46,688 shares of Faeth Therapeutics common stock. The footnotes state that Stephenson is the sole trustee of the revocable trust, with sole voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported a series of open-market purchases of the company’s common stock. Over June 22–23, 2026, the trust bought a total of 17,413 shares in eight separate transactions.
The reported weighted average purchase prices ranged from about $19.5765 to $26.31 per share across those trades. All holdings reported in this filing are indirect, held by the revocable trust for which Stephenson serves as sole trustee with sole voting and investment power, and amount to 17,413 shares after these transactions.
Faeth Therapeutics, Inc. President and CEO Anand Kiran Parikh increased his direct stake through option exercises and an open-market stock purchase. He exercised employee stock options to acquire 53,465 shares of common stock at $1.16 per share and bought an additional 2,806 shares in the open market at $19.76 per share, all on June 22, 2026. Following these transactions, he directly owns 817,699 shares of Faeth Therapeutics common stock.
Sensei Biotherapeutics, Inc. director Saira Ramasastry received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $13.00 per share and expire on June 11, 2036.
The options vest in 36 equal monthly installments over three years, so they are fully vested by June 12, 2029, as long as she continues serving with the company. After this grant, she holds options for 25,000 shares directly.
Sensei Biotherapeutics, Inc. President and CEO Anand Kiran Parikh converted preferred shares received in a merger into common stock. He acquired 761,428 shares of Common Stock through the conversion of 761.428 shares of Series B Preferred Stock, which are convertible into 1,000 common shares each with no expiration date. The Series B Preferred Stock had been issued as consideration when Faeth Holdings Therapeutics, Inc. common stock was converted into the right to receive these preferred shares at the closing of a multi‑step merger involving Faeth and its holding entities.
Sensei Biotherapeutics director Stephen M. Hahn reported acquiring common shares through a preferred stock conversion and receiving a new stock option award. On June 15, 2026, 44,763 shares of Common Stock were acquired upon the conversion of 44.763 shares of Series B Preferred Stock, leaving him with 44,763 common shares directly owned.
Separately, on June 12, 2026, Hahn received a stock option for 25,000 shares of Common Stock at an exercise price of $13.00 per share. This option vests in 36 equal monthly installments and is expected to be fully vested by June 12, 2029, subject to his continued service with the company.
Sensei Biotherapeutics, Inc. reported that President and CEO Anand Kiran Parikh received new equity awards connected to the Faeth Holdings Therapeutics merger. He was granted options to buy 136,884 shares of common stock at $1.16 per share, plus an additional option for 12,320 shares at the same exercise price. He also acquired 761.428 shares of Series B Non-Voting Convertible Preferred Stock, which are convertible into 761,428 shares of common stock. The footnotes explain these awards were received in exchange for Faeth common stock and Faeth stock options under the merger agreement, with vesting schedules that run in monthly installments through early 2027.
Sensei Biotherapeutics, Inc. reported that its President & PEO, Gerry Christopher, received a grant of stock options covering 220,000 shares of common stock. The options have an exercise price of $29.89 per share and were approved under the company’s 2026 Equity Incentive Plan after stockholder approval.
According to the vesting terms, 25% of the option vests and becomes exercisable on April 10, 2027, with the remaining shares vesting in 36 equal monthly installments so that the award is fully vested by April 10, 2030, contingent on his continued service with the company.
Sensei Biotherapeutics director Phillip B. Donenberg received a stock option grant covering 12,500 shares of common stock. The option has an exercise price of $11.41 per share and expires on June 9, 2036.
The award vests in 12 equal monthly installments over one year, so it becomes fully vested on June 10, 2027, as long as Donenberg continues to provide service to the company on each vesting date. After this grant, he holds options for 12,500 shares directly.
Sensei Biotherapeutics director Bob Holmen received a grant of stock options for 12,500 shares of Common Stock. The options have an exercise price of $11.41 per share and expire on June 9, 2036. They vest in 12 equal monthly installments over one year, becoming fully vested on June 10, 2027, subject to his continuous service. Following this award, he holds 12,500 options directly.
Cambrian BioPharma Inc, a ten percent owner of Sensei Biotherapeutics, Inc., reported open-market sales of a total of 25,000 shares of Sensei common stock. The trades on June 1, 2026 were executed at prices ranging from $20.00 to $21.00 per share, based on a weighted average price disclosure.
Sensei Biotherapeutics, Inc. ten percent owner James Peyer reported open-market sales of 25,000 shares of Common Stock. The sales occurred on June 1, 2026 in two transactions: 24,524 shares at $20.00 per share and 476 shares at $21.14 per share.
After these transactions, he continued to hold more than 130,000 shares of Common Stock directly. A footnote explains that one reported price reflects a weighted average for trades executed in a range from $20.00 to $21.00, with detailed breakdowns available upon request.
Sensei Biotherapeutics, Inc. reported that entities associated with Millennium Management LLC actively traded its Common Stock over several days in early April 2026. The trades were made by ICS Opportunities II LLC and other trading entities, with voting control and investment discretion held by Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
Across these open-market transactions, the reporting entities sold 17,076 shares and purchased 4,215 shares of Common Stock at prices generally between $28.9417 and $35.5472 per share, resulting in a net sale. After the final transaction, Millennium Management LLC beneficially owned 133,986 shares indirectly, as disclosed in column 5. Each reporting person disclaims beneficial ownership beyond any pecuniary interest.
Entities associated with Millennium Management LLC reported active trading in Sensei Biotherapeutics, Inc. common stock over March 31 and April 1, 2026. Across multiple open-market purchases and sales, they were net buyers of 9,439 shares, with 12,180 shares purchased and 2,741 shares sold. Following these transactions, Millennium Management LLC beneficially owned 147,731 shares of Sensei common stock indirectly. The trades were executed by ICS Opportunities II LLC or other trading entities under Millennium’s voting control, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.
Sensei Biotherapeutics, Inc. reported a series of open-market trades in its Common Stock by entities associated with Millennium Management LLC over March 26–30, 2026. The trades were executed by ICS Opportunities II LLC or other trading entities subject to voting control and investment discretion by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander.
Across these dates, the entities reported purchases of 30,585 shares and sales of 3,250 shares, resulting in a net purchase of 27,335 shares of Sensei Biotherapeutics Common Stock. Following the transactions on March 30, 2026, Millennium Management LLC is reported as beneficially owning 145,678 shares, with each reporting person disclaiming beneficial ownership beyond any pecuniary interest.
Sensei Biotherapeutics’ principal financial and accounting officer, Josiah Craver, received a grant of stock options covering 80,000 shares of common stock on April 10, 2026. The options have an exercise price of $29.89 per share and expire on April 9, 2036.
According to the vesting terms, 25% of the shares subject to the option vest and become exercisable on April 10, 2027, with the remaining shares vesting in 36 equal monthly installments so that the award is fully vested by April 10, 2030, subject to his continuous service with the company.
Sensei Biotherapeutics director Phillip B. Donenberg received a supplemental stock option grant for 23,100 shares of Common Stock. The option has an exercise price of $29.89 per share and expires on April 9, 2036. This award aligns his total initial director option grant with the company’s amended non-employee director compensation policy, which now provides 25,000 options to new directors. The new options vest in 36 equal monthly installments over three years, fully vesting on April 10, 2029, contingent on his continued service as a director.
Sensei Biotherapeutics, Inc. reported that Chief Operating Officer Anand Kiran Parikh acquired several equity awards in connection with the Faeth transaction and new compensation grants. On February 19, 2026, he received 1,239,305 employee stock options with a stated price of $0.00 per share. On February 17, 2026, he acquired 809,822 shares of Series B Non-Voting Convertible Preferred Stock and additional employee stock options covering 92,533 and 56,673 shares, all recorded as awards at $0.00 per share.
Footnotes explain that each share of Series B Preferred Stock is convertible into 1,000 shares of common stock with no expiration date and was received in exchange for 4,062,777 shares of Faeth Holdings Therapeutics, Inc. common stock under a Merger Agreement among Sensei, two Sapphire Merger Subs, HoldCo and Faeth. Other footnotes state that certain options were received in exchange for Faeth stock options with a $0.23 exercise price, with one such option vesting in 48 equal monthly installments beginning August 1, 2022. A separate option grant is immediately exercisable, while another vests 25% on February 19, 2027 and the remainder in 36 equal monthly installments thereafter.
Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.